William R. Sellers
Molecular Biology · 2000–2020
A researcher in the Science corpus: 27 papers; trusts 1 researcher and is trusted by 3 researchers here, as inferred from the citation graph.
Subfields
- Molecular Biology — 269 citations into it; #11,345 of 17,773 by trust here, #561 by citations
Whom William R. Sellers trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts William R. Sellers overall
Papers from William R. Sellers's perspective
Ordered by how strongly the researchers William R. Sellers trusts endorse each paper. Same corpus, a different order for every researcher.
- Controlling the false discovery rate: a practical and powerful approach to multiple testing
- Accurate Whole Human Genome Sequencing using Reversible Terminator Chemistry (Nature)
- Summaries of Affymetrix GeneChip probe level data. (Nucleic Acids Research)
- Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments (Statistical Applications in Genetics and Molecular Biology)
- Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. (New England Journal of Medicine)
- Biological sequence analysis
- Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. (Proceedings of the National Academy of Sciences of the United States of America)
- Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor… (Cancer Research)
- ggplot2 - Elegant Graphics for Data Analysis (2nd Edition)
- Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways (Science)
Their papers
- The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity (2012) — 7,455 citations
- Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma (2007) — 1,099 citations
- mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways (2004) — 980 citations
- Gene expression correlates of clinical prostate cancer behavior. (2002) — 2,634 citations
- The biology and clinical relevance of the PTEN tumor suppressor pathway. (2004) — 971 citations
- BRAF mutation predicts sensitivity to MEK inhibition (2006) — 1,346 citations
- Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma (2005) — 1,567 citations
- Phosphorylation of the PTEN Tail Regulates Protein Stability and Function (2000) — 812 citations
- Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening. (2017) — 599 citations
- Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974 (2013) — 803 citations
- Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants (2005) — 677 citations
- Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance (2013) — 736 citations
- Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity (2008) — 1,165 citations
- MEK1 mutations confer resistance to MEK and B-RAF inhibition (2009) — 656 citations
- COT/MAP3K8 drives resistance to RAF inhibition through MAP kinase pathway reactivation (2010) — 731 citations
- dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data (2004) — 401 citations
- Focal Gains of Vascular Endothelial Growth Factor A and Molecular Classification of Hepatocellular Carcinoma (2008) — 647 citations
- Next-generation characterization of the Cancer Cell Line Encyclopedia (2019) — 2,830 citations
- Quantitative Proteomics of the Cancer Cell Line Encyclopedia (2020) — 836 citations
- Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases (2016) — 795 citations